Search

EHA-MHTT joint membership

Save money and time by becoming a joint member of EHA and the Magyar Hematológiai és Transzfuziológiai Társaság. We've joined forces with the Magyar Hematológiai és Transzfuziológiai Társaság (MHTT) to offer a special joint membership deal.

EHA-SFH joint membership

Save money and time by becoming a joint member of EHA and the Société Française d’Hématologie. We've joined forces with the Société Française d’Hématologie (SFH) to offer a special joint membership deal.

EHA-SPH joint membership

Save money and time by becoming a joint member of EHA and the Sociedade Portuguesa de Hematologia. We've joined forces with the Sociedade Portuguesa de Hematologia (SPH) to offer a special joint membership deal.

EHA-SRH joint membership

Save money and time by becoming a joint member of EHA and the Societatea Română de Hematologie. We've joined forces with the Societatea Română de Hematologie (SRH) to offer a special joint membership deal.

EHA-THD joint membership

Save money and time by becoming a joint member of EHA and the Türk Hematoloji Derneği. We've joined forces with the Türk Hematoloji Derneği (THD) to offer a special joint membership deal.

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

Jun 12 2015

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

Mutiple Myeloma at the 19th Congress of the European Hematology Association: What is new?

May 21 2014 Posted in Press releases

During the meeting, recently developed approaches for diagnosis and monitoring will be presented. Gene-expression-profiling to detect molecular subgroups with a different prognosis and high-throughput-sequencing to identify new genetic lesions will be discussed.

SWG Educational Activities

Recruitment trialsRecruitment is underway for the following trials:

Trial on precision hematology: Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies (EXALT-2); ClinicalTrials.